Therapeutic drug monitoring of gentamicin: A 6-year follow-up audit

Journal of Clinical Pharmacy and Therapeutics

Volumn 22, Issue 1, 1997, Pages 21-25

  Ismail, R ^a,b   Haq, A H S M ^b   Azman, M ^a   Rahman, A F A ^a,b  

^a HOSPITAL UNIVERSITI SAINS MALAYSIA   (Malaysia)

^b SCHOOL OF HEALTH SCIENCES   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

GENTAMICIN;

ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEWBORN;

EID: 0030811502     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1997.96375963.x     Document Type: Article

References (14)

1. Rodvold KA, Pryka RD, Kuehl PG, Blum RA, Donahue P. (1990) Bayesian forecasting of serum gentamicin concentrations in intensive care patients. Clinical Pharmacokinetics, 18(5), 409-418.
2. Burton ME, Chou MSS, Platt DR, et al. (1985) Comparison of drug dosing methods. Clinical Pharmacokinetics, 10, 1-37.
3. Barza M, Brown RD, Shen D, Gibaldi M, Weinstein L. (1975) Predictability of blood levels of gentamicin in man. Journal of Infectious Diseases, 132, 165-174.
4. Cohen LB, Birmingham PH. (1981) Effect of pharmacist intervention on the use of serum drug assays. American Journal of Hospital Pharmacy, 38, 845-851.
5. Zaske DE, Cipolle RJ, Rotschafer JC, et al. (1982) Gentamicin pharmacokinetics in 1640 patients: Method for control of serum concentrations. Antimicrobial Agents and Chemotherapy, 10, 1-37.
6. Ismail R, Sarriff A, Rahman AFA. (1990) Therapeutic drug monitoring for gentamicin in Hospital University Sains Malaysia. Medical Journal of Malaysia, 45, 57-64.
7. Kubota K, Suganuma T, Sasaki T, Ishizaki T. (1988) An approach to forecast aminoglycoside nephrotoxicity from routinely collected clinical data. Therapeutic Drug Monitoring, 10, 401-420.
8. Destache CJ, Meyer SK, Bittner MJ, Herma KG. (1990) Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. Therapeutic Drug Monitoring, 12, 419-426.
9. Zaske DE. (1991) Aminoglycosides. In: Applied Pharmacokinetics. eds Evans WE, Shentag JJ, Jusko WJ, 2nd edn, Applied Therapeutics Inc, Spokane, WA.
10. Hewitt WL. (1974) Gentamicin: toxicity in perspective. Postgraduate Medical Journal 505, 55-59.
11. Jeresjo GS, Bradley AB, Dole EJ, et al. (1989) Risk of renal dysfunction in critically ill trauma patients receiving aminoglycosides. Clinical Pharmacy, 8, 43-47.
12. Sawyers CL, Moore RD, Lerner SA, Smith CR. (1986) A model for predicting nephrotoxicity in patients treated with aminoglycosides. Journal of Infectious Diseases, 153, 1062-1068.
13. Hull JH, Sarubbi FA. (1976) Gentamicin serum concentrations: pharmacokinetic predictions. Annals of Internal Medicine 85, 183-189.
14. Bertino JS, Booker LA, Franck PA, et al. (1993) Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. Journal of Infectious Diseases, 167, 173-179.